#United States #Salt Lake City #Lipocine #LPCN 1148 #cirrhosis

Lipocine's LPCN 1148 Recognized in Hepatology

In a significant development for liver disease management, Lipocine Inc. (NASDAQ: LPCN) has announced that its investigational product, LPCN 1148, has been highlighted in the “Hepatology Highlights” section of the June 2025 edition of Hepatology. This recognition underscores the potential of LPCN 1148, particularly for male patients suffering from cirrhosis. The article titled "LPCN 1148 Rebuilding Muscle Memory in Cirrhosis Patients" was authored by Dr. Kevin Harris from the Mayo Clinic's Division of Gastroenterology and Hepatology.

LPCN 1148 aims to become a First in Class therapy, introducing a unique mechanism of action for the management of conditions such as overt hepatic encephalopathy (HE) and sarcopenia. The promising results from the Phase 2 study are reported in the same journal issue, offering details from Stage 1 of the trial where 29 participants were randomized to receive either LPCN 1148 or a placebo over a 24-week period.

Clinical Implications

Mahesh Patel, CEO of Lipocine, expressed optimism about the potential impact of LPCN 1148, stating, "This coverage of LPCN 1148 in Hepatology reflects the growing recognition of LPCN 1148 for management of cirrhosis. Treatment options for sarcopenia in cirrhosis are quite limited, primarily revolving around dietary adjustments and physical exercise. Having LPCN 1148 recognized in such a premier journal highlights our innovative approach to enhance patient outcomes."

Cirrhosis, a severe liver condition, affects numerous individuals and presents severe health challenges. It can develop from various causes such as alcohol abuse, chronic viral hepatitis, nonalcoholic fatty liver disease, and primary cholangitis. Patients with cirrhosis often experience complications including hepatic encephalopathy and a decreased muscle mass known as sarcopenia, which significantly impacts their quality of life.

The publication of LPCN 1148’s results contributes to an urgent need for effective treatments for over 382,000 diagnosed cases of decompensated liver cirrhosis in the U.S., where treatment options are generally scarce and often lead to waiting for a liver transplant.

Phase 2 Study Outcomes

The Phase 2 study of LPCN 1148 is noteworthy as it not only aims to improve the quality of life for patients awaiting liver transplants but also seeks to reduce the recurrence of severe complications like HE. The research conducted in multiple centers across the United States included assessments every four weeks, with comprehensive CT scans to measure muscle mass changes. Notably, there were no limitations on standard care medications throughout the trial.

Dr. Harris emphasized the importance of this innovative therapy, stating that HE poses a severe threat to those with liver disease. The disorder manifests with neurological symptoms that greatly compromise patients' well-being. Approximately 50% of people with cirrhosis might encounter episodes of HE during their lives, making adequate management crucial.

Looking Ahead for Lipocine

Lipocine and its clinical teams are now looking for partnerships to further explore the development of LPCN 1148. Having received Fast Track Designation from the FDA as a treatment for sarcopenia in decompensated cirrhosis patients, the company is at a pivotal stage in its journey, addressing long-standing challenges in liver disease management. The potential of LPCN 1148 represents not just a treatment option but possibly a significant turning point in the standard care for individuals enduring the burdens of cirrhosis.

In conclusion, the recognition of LPCN 1148 in the Hepatology journal not only elevates its profile in the research community but also shines a light on the pivotal role of innovative treatments addressing unmet medical needs in liver health. Lipocine remains devoted to fostering advancements that enhance both patient quality of life and clinical outcomes.